PL2211892T3 - Kompozycje zawierające peptydy zasadowych białek mieliny i ich zastosowanie medyczne - Google Patents

Kompozycje zawierające peptydy zasadowych białek mieliny i ich zastosowanie medyczne

Info

Publication number
PL2211892T3
PL2211892T3 PL08844568T PL08844568T PL2211892T3 PL 2211892 T3 PL2211892 T3 PL 2211892T3 PL 08844568 T PL08844568 T PL 08844568T PL 08844568 T PL08844568 T PL 08844568T PL 2211892 T3 PL2211892 T3 PL 2211892T3
Authority
PL
Poland
Prior art keywords
basic protein
myelin basic
compositions
protein peptides
medical uses
Prior art date
Application number
PL08844568T
Other languages
English (en)
Inventor
David Wraith
Heather Streeter
Original Assignee
Apitope Tech Bristol Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0721430A external-priority patent/GB0721430D0/en
Priority claimed from GB0800962A external-priority patent/GB0800962D0/en
Application filed by Apitope Tech Bristol Limited filed Critical Apitope Tech Bristol Limited
Publication of PL2211892T3 publication Critical patent/PL2211892T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10Peptides having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0008Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55516Proteins; Peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0007Nervous system antigens; Prions
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Confectionery (AREA)
PL08844568T 2007-10-31 2008-10-30 Kompozycje zawierające peptydy zasadowych białek mieliny i ich zastosowanie medyczne PL2211892T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0721430A GB0721430D0 (en) 2007-10-31 2007-10-31 Composition
GB0800962A GB0800962D0 (en) 2008-01-18 2008-01-18 Conposition
EP08844568A EP2211892B1 (en) 2007-10-31 2008-10-30 Compositions comprising myelin basic protein peptides and medical uses thereof
PCT/GB2008/003673 WO2009056833A2 (en) 2007-10-31 2008-10-30 Composition

Publications (1)

Publication Number Publication Date
PL2211892T3 true PL2211892T3 (pl) 2012-01-31

Family

ID=40591554

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08844568T PL2211892T3 (pl) 2007-10-31 2008-10-30 Kompozycje zawierające peptydy zasadowych białek mieliny i ich zastosowanie medyczne

Country Status (23)

Country Link
US (3) US8623827B2 (pl)
EP (1) EP2211892B1 (pl)
JP (1) JP5361895B2 (pl)
KR (1) KR101570383B1 (pl)
CN (1) CN101848725B (pl)
AT (1) ATE518546T1 (pl)
AU (1) AU2008320657B2 (pl)
BR (1) BRPI0818302B1 (pl)
CA (1) CA2703170C (pl)
CY (1) CY1112620T1 (pl)
DK (1) DK2211892T3 (pl)
EA (1) EA017999B1 (pl)
EC (1) ECSP10010211A (pl)
HR (1) HRP20110724T1 (pl)
IL (1) IL204662A (pl)
MX (1) MX2010004698A (pl)
MY (1) MY158800A (pl)
NZ (1) NZ583924A (pl)
PL (1) PL2211892T3 (pl)
PT (1) PT2211892E (pl)
SI (1) SI2211892T1 (pl)
WO (1) WO2009056833A2 (pl)
ZA (1) ZA201001748B (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE401343T1 (de) 2000-08-21 2008-08-15 Apitope Technology Bristol Ltd Tolerogenische peptide
WO2009056833A2 (en) 2007-10-31 2009-05-07 Apitope Technology (Bristol) Limited Composition
JP5709876B2 (ja) * 2009-10-12 2015-04-30 ライフバイオ ラボラトリーズ エルエルシーLIFEBio LABORATORIES LLC 多発性硬化症治療用組成物
GB201300684D0 (en) * 2013-01-15 2013-02-27 Apitope Int Nv Peptide
GB201603582D0 (en) * 2016-03-01 2016-04-13 Apitope Int Nv Peptides
EP3565585B1 (en) * 2017-01-04 2024-11-13 Worg Pharmaceuticals (Zhejiang) Co., Ltd. Therapeutic method using dose escalation protocol for tolerogenic peptides
GB201700095D0 (en) * 2017-01-04 2017-02-22 Apitope Int Nv Composition
EP3668535A1 (en) * 2017-08-14 2020-06-24 Apitope Technology (Bristol) Limited Method
MX2023012257A (es) 2021-04-16 2024-01-08 Cour Pharmaceuticals Dev Company Inc Método de rastreo del mantenimiento de la inmunotolerancia.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5817629A (en) * 1991-10-22 1998-10-06 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
ATE401343T1 (de) * 2000-08-21 2008-08-15 Apitope Technology Bristol Ltd Tolerogenische peptide
AU2002249779A1 (en) 2000-12-01 2002-08-12 Regents Of The University Of Minnesota Method to treat hemophilia
GB0202399D0 (en) * 2002-02-01 2002-03-20 Univ Bristol Peptide
WO2009056833A2 (en) 2007-10-31 2009-05-07 Apitope Technology (Bristol) Limited Composition

Also Published As

Publication number Publication date
EP2211892B1 (en) 2011-08-03
DK2211892T3 (da) 2011-10-31
HK1142803A1 (en) 2010-12-17
US8623827B2 (en) 2014-01-07
AU2008320657B2 (en) 2013-09-05
BRPI0818302A2 (pl) 2018-08-21
NZ583924A (en) 2012-06-29
US20100286054A1 (en) 2010-11-11
PT2211892E (pt) 2011-10-18
JP5361895B2 (ja) 2013-12-04
JP2011500776A (ja) 2011-01-06
AU2008320657A1 (en) 2009-05-07
CN101848725A (zh) 2010-09-29
US9775880B2 (en) 2017-10-03
KR20100036391A (ko) 2010-04-07
KR101570383B1 (ko) 2015-11-19
IL204662A0 (en) 2010-11-30
BRPI0818302B1 (pt) 2022-04-12
CA2703170C (en) 2016-10-11
CY1112620T1 (el) 2016-02-10
US20160263188A1 (en) 2016-09-15
CN101848725B (zh) 2013-05-22
US9381234B2 (en) 2016-07-05
ZA201001748B (en) 2011-06-29
WO2009056833A2 (en) 2009-05-07
MX2010004698A (es) 2010-05-13
EP2211892A2 (en) 2010-08-04
IL204662A (en) 2013-07-31
MY158800A (en) 2016-11-15
HRP20110724T1 (hr) 2011-12-31
SI2211892T1 (sl) 2011-12-30
ATE518546T1 (de) 2011-08-15
EA201070541A1 (ru) 2010-12-30
US20140161832A1 (en) 2014-06-12
ECSP10010211A (es) 2010-08-31
CA2703170A1 (en) 2009-05-07
EA017999B1 (ru) 2013-04-30
WO2009056833A3 (en) 2009-11-26

Similar Documents

Publication Publication Date Title
PT2211892E (pt) Composições compreendendo péptidos de proteína básica de mielina e suas utilizações médicas
TW201129377A (en) Binding proteins that bind to human FGFR1c, human β-Klotho and both human FGFR1c and human β-Klotho
EA201490644A1 (ru) Терапевтические пептиды
EA201171220A1 (ru) Мутанты fgf21 и их применение
EA201001883A1 (ru) Мутанты fgf21 и их применение
EA201270528A1 (ru) Композиции цитокинов семейства il-17 и их применение
MX2015011199A (es) Agentes terapéuticos de csf1.
CY1118454T1 (el) Πρωτοτυποι αναστολεις πυρρολιου της αναγωγασης s-νιτροζογλουταθειονης ως θεραπευτικοι παραγοντες
IN2012DN02589A (pl)
WO2009129246A3 (en) Compositions and methods for preparing and using same
MX2009004038A (es) Gel de diclofenaco.
MX2009009200A (es) Tratamiento de enfermedades caracterizadas por la inflamacion.
EP4414376A3 (en) Novel depsipeptide and uses thereof
EA200701825A1 (ru) Вакцины против хламидиоза
MX2011011768A (es) Composiciones y metodos de uso para moleculas de enlace a dickkopf-1 o dickkopf-4 o a ambos.
MX2009004862A (es) Estabilizacion de vacunas por liofilizacion.
PH12017501473A1 (en) Novel proteins specific for pyoverdine and pyochelin
MX2010005589A (es) Composicion para el cuidado personal.
WO2010064012A3 (en) Treatment of autoimmune disease by modulating annexin-i (lipocortin 1 )
WO2007075439A3 (en) Compositions and methods for treating obesity and related metabolic disorders
WO2012090207A3 (en) Par1 and par2 c-tail peptides and peptide mimetics
WO2010041827A3 (en) NF-κB INHIBITOR CONTAINING ARH1 PROTEIN OR GENE ENCODING THE SAME
GB0818080D0 (en) Immunogenic peptides
GB0423126D0 (en) Protein
MX2009002717A (es) Composiciones y metodos para tratamiento del sindrome de fatiga cronica y enfermedades neurodegenerativas.